CDC20 contributes to the development of human cutaneous squamous cell carcinoma through the Wnt/β‑catenin signaling pathway

• Published in: International journal of oncology Vol. 54; no. 5; pp. 1534 - 1544
• Main Authors: Chu, Zhaowei, Zhang, Xinyue, Li, Qingyan, Hu, Guanglei, Lian, Christine Guo, Geng, Songmei
• Format: Journal Article
• Language: English
• Published: Greece Spandidos Publications UK Ltd 27.02.2019; D.A. Spandidos
• Subjects: Biomarkers; Cancer therapies; Cell cycle; Cell division; Cell growth; Dermatology; Family medical history; Gene expression; Melanoma; Patients; Proteins; Skin cancer; Squamous cell carcinoma; Studies; United States > US; China
• ISSN: 1019-6439; 1791-2423
• DOI: 10.3892/ijo.2019.4727

Cell division cycle 20 (CDC20) is a regulatory molecule and serves critical roles at multiple points of the cell cycle. Recent evidence indicates that CDC20 may serve an oncogenic role in a number of human cancer types. However, the role of CDC20 in primary cutaneous squamous cell carcinoma (cSCC) has not been studied, to the best of our knowledge. The aim of the present study was to investigate whether and how CDC20 is involved in the tumorigenesis of cSCC. The results revealed that CDC20 expression was significantly increased in cSCC tissues and cell lines, and its expression was associated with pathological differentiation. Downregulation of CDC20 inhibited cell proliferation, induced cell cycle arrest, promoted apoptosis and reduced migratory ability through inhibition of the Wnt/β‑catenin signaling pathway. Furthermore, all‑trans‑retinoic acid treatment significantly downregulated CDC20 expression in cSCC. The present results revealed that CDC20 may serve a crucial role in human cSCC, and suggested that CDC20 may be a novel biomarker for the prevention, diagnosis and treatment of cSCC.